Detailed Mechanism Funding and Narrative

Details for Mechanism ID: 17501
Country/Region: Zambia
Year: 2014
Main Partner: University Teaching Hospital - Zambia
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $1,568,400 Additional Pipeline Funding: $216,600

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Since 2002, the Government of the Republic of Zambia (GRZ) has implemented the treatment of HIV through the use of antiretroviral medications (ARVs) and the wholesome management of the HIV infected individual

The UTH-HLAB programme priorities will continue to be aligned to the Zambian government policies and plans for the management and control of HIV infections. The programme will also work in concert with the five PEPFAR approaches; (integration, continuum of the HIV response, attention to specific vulnerable populations, Country ownership and evidence based programming.

Activities will include the training of a critical mass of Master Trainers in advanced HIV/AIDS prevention, care and treatment; mentorship and clinical evaluations of HIV and AIDS programs; domestication and timely revision of HIV/AIDS related international guidelines and training manuals.

In line with government policy to provide quality laboratory services, the programme will continue to support the UTH laboratories in supporting the implementation of the quality management systems with the view of having the laboratories accredited.

Emphasis in the coming years will be on using local resources from the government and UTH to support the provision of laboratory services, maintenance of the equipment and laboratory infrastructure.

Monitoring and evaluation will be achieved through the collection, aggregation and transmission of core indicator data from service delivery points to inform clinic and program management decisions at all levels, using the health management information system (HMIS). This will involve ensuring data quality, transmission, exchange formats, security and confidentiality.

Mechanism Allocation by Budget Code for Selected Year
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $1,568,400
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
C2.1.D By Age: <15 2015 2,000
C2.1.D By Age: 15+ 2015 4,000
C2.1.D By Age/Sex: <15 Female 2015 1,000
C2.1.D By Age/Sex: <15 Male 2015 1,000
C2.1.D By Age/Sex: 15+ Female 2015 3,800
C2.1.D By Age/Sex: 15+ Male 2015 200
C2.1.D By Sex: Female 2015 4,800
C2.1.D By Sex: Male 2015 1,200
C2.1.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 6,000
C2.1.D Sum of Age disaggregates 2015 6,000
C2.1.D Sum of Age/Sex disaggregates 2015 6,000
C2.1.D Sum of Sex disaggregates 2015 6,000
C2.1.D_NGI By Age: <15 2015 2,000
C2.1.D_NGI By Age: 15+ 2015 4,000
C2.1.D_NGI By Age/Sex: <15 Female 2015 1,000
C2.1.D_NGI By Age/Sex: <15 Male 2015 1,000
C2.1.D_NGI By Age/Sex: 15+ Female 2015 3,800
C2.1.D_NGI By Age/Sex: 15+ Male 2015 200
C2.1.D_NGI By Sex: Female 2015 4,800
C2.1.D_NGI By Sex: Male 2015 1,200
C2.1.D_NGI Number of HIV-positive individuals receiving a minimum of one clinical service 2015 6,000
C2.1.D_NGI Sum of Age disaggregates 2015 6,000
C2.1.D_NGI Sum of Age/Sex disaggregates 2015 6,000
C2.1.D_NGI Sum of Sex disaggregates 2015 6,000
C2.4.D Number of HIV-positive individuals receiving a minimum of one clinical service 2015 6,000
C2.4.D Number of HIV-positive patients who were screened for TB in HIV care or treatment setting 2015 6,000
CARE_CURR Age/sex: <1 Female 2015 60
CARE_CURR Age/sex: <1 Male 2015 60
CARE_CURR Age/sex: 1-4 Female 2015 448
CARE_CURR Age/sex: 1-4 Male 2015 448
CARE_CURR Age/sex: 10-14 Female 2015 150
CARE_CURR Age/sex: 10-14 Male 2015 146
CARE_CURR Age/sex: 15-19 Female 2015 60
CARE_CURR Age/sex: 15-19 Male 2015 60
CARE_CURR Age/sex: 5-9 Female 2015 1,034
CARE_CURR Age/sex: 5-9 Male 2015 1,034
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 1,542
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,542
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 210
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 206
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,500
CARE_CURR Sum of Age/Sex disaggregates 2015 3,500
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 3,500
CARE_NEW Age/sex: <1 Female 2015 19
CARE_NEW Age/sex: <1 Male 2015 18
CARE_NEW Age/sex: 1-4 Female 2015 37
CARE_NEW Age/sex: 1-4 Male 2015 36
CARE_NEW Age/sex: 10-14 Female 2015 32
CARE_NEW Age/sex: 10-14 Male 2015 31
CARE_NEW Age/sex: 15-19 Female 2015 13
CARE_NEW Age/sex: 15-19 Male 2015 13
CARE_NEW Age/sex: 5-9 Female 2015 25
CARE_NEW Age/sex: 5-9 Male 2015 26
CARE_NEW Aggregated Age/sex: <15 Female 2015 126
CARE_NEW Aggregated Age/sex: <15 Male 2015 124
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 250
CARE_NEW Sum of Age/sex disaggregates 2015 250
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 250
CARE_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 2
CARE_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services 2015 2
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 2
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 2
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 2
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
FN_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 2
FN_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 2
FN_SITE Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 2
FN_SITE Sum of Numerator Support Type disaggregates 2015 2
FN_SITE Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 2
FN_SITE_den Sum of Denominator Support Type disaggregates 2015 2
FN_THER Age: <1 2015 40
FN_THER Age: 1-4 2015 55
FN_THER Age: 15-17 2015 20
FN_THER Age: 5-14 2015 135
FN_THER Aggregated Age: <18 2015 250
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2015 250
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2015 250
FN_THER Sum of Age disaggregates 2015 250
FN_THER Sum of Aggregated Age disaggregates 2015 250
HTS_TST Age/sex: <1 Female 2015 1,500
HTS_TST Age/sex: <1 Female 2015 1,500
HTS_TST Age/sex: <1 Male 2015 1,500
HTS_TST Age/sex: <1 Male 2015 1,500
HTS_TST Age/sex: 1-4 Female 2015 688
HTS_TST Age/sex: 1-4 Female 2015 688
HTS_TST Age/sex: 1-4 Male 2015 688
HTS_TST Age/sex: 1-4 Male 2015 688
HTS_TST Age/sex: 10-14 Female 2015 150
HTS_TST Age/sex: 10-14 Female 2015 150
HTS_TST Age/sex: 10-14 Male 2015 150
HTS_TST Age/sex: 10-14 Male 2015 150
HTS_TST Age/sex: 15-19 Female 2015 2,118
HTS_TST Age/sex: 15-19 Female 2015 2,118
HTS_TST Age/sex: 15-19 Male 2015 2,118
HTS_TST Age/sex: 15-19 Male 2015 2,118
HTS_TST Age/sex: 20-24 Female 2015 4,235
HTS_TST Age/sex: 20-24 Female 2015 4,235
HTS_TST Age/sex: 20-24 Male 2015 4,235
HTS_TST Age/sex: 20-24 Male 2015 4,235
HTS_TST Age/sex: 25-49 Female 2015 8,631
HTS_TST Age/sex: 25-49 Female 2015 8,631
HTS_TST Age/sex: 25-49 Male 2015 8,631
HTS_TST Age/sex: 25-49 Male 2015 8,631
HTS_TST Age/sex: 5-9 Female 2015 375
HTS_TST Age/sex: 5-9 Female 2015 375
HTS_TST Age/sex: 5-9 Male 2015 375
HTS_TST Age/sex: 5-9 Male 2015 375
HTS_TST Age/sex: 50+ Female 2015 1,803
HTS_TST Age/sex: 50+ Female 2015 1,803
HTS_TST Age/sex: 50+ Male 2015 803
HTS_TST Age/sex: 50+ Male 2015 803
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,713
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,713
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 16,787
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 15,787
HTS_TST Aggregated Age/sex: <15 Female 2015 2,713
HTS_TST Aggregated Age/sex: <15 Male 2015 2,713
HTS_TST Aggregated Age/sex: 15+ Female 2015 16,787
HTS_TST Aggregated Age/sex: 15+ Male 2015 15,787
HTS_TST By Test Result: Negative 2015 33,327
HTS_TST By Test Result: Negative 2015 33,327
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 38,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 38,000
HTS_TST Sum of Age/Sex disaggregates 2015 38,000
HTS_TST Sum of Age/Sex disaggregates 2015 38,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,426
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,426
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 32,574
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 32,574
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 38,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 38,000
HTS_TST Sum of Test Result disaggregates 2015 38,000
HTS_TST Sum of Test Result disaggregates 2015 38,000
HTS_TST_POS By Test Result: Positive 2015 4,673
HTS_TST_POS By Test Result: Positive 2015 4,673
LAB_ACC By site support type: Direct Service Delivery (DSD) 2015 1
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2015 1
LAB_ACC Sum of Support Type disaggregates 2015 1
LAB_CAP By clinical laboratories 2015 1
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 1
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 1
LAB_CAP Sum of Site Support Type disaggregates 2015 1
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT CD4: Number of laboratories that participate in this PT program 2015 1
LAB_PT CD4: Number of laboratories that perform this testing 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2015 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2015 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2015 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2015 1
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2015 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2015 1
LAB_PT Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program 2015 1
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2015 1
LAB_PT TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing 2015 1
OVC_ACC Age: 10-14 2015 164
OVC_ACC Age: 15-17 2015 133
OVC_ACC Age: 18+ 2015 294
OVC_ACC Age: 5-9 2015 71
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 662
OVC_ACC Sex: Female 2015 430
OVC_ACC Sex: Male 2015 232
OVC_ACC Sum of Age disaggregates 2015 662
OVC_ACC Sum of Sex disaggregates 2015 662
OVC_SERV Age: 10-14 2015 164
OVC_SERV Age: 15-17 2015 133
OVC_SERV Age: 18+ 2015 294
OVC_SERV Age: 5-9 2015 71
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 662
OVC_SERV Sex: Female 2015 430
OVC_SERV Sex: Male 2015 232
OVC_SERV Sum of Age disaggregates 2015 662
OVC_SERV Sum of Sex disaggregates 2015 662
PMTCT_ARV Life-long ART (including Option B+) 2015 4,693
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 4,925
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 4,693
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 4,518
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 175
PMTCT_ARV Sum of New and Current disaggregates 2015 4,693
PMTCT_ARV Sum of Regimen Type disaggregates 2015 4,693
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 4,693
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 4,925
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 4,693
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 4,518
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 175
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 4,693
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 4,693
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 2,112
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 235
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 286
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 4,693
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 2,347
PMTCT_EID Sum of Infant Age disaggregates 2015 2,347
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 1
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 1
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 1
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 1
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 1
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 1
PMTCT_STAT By: Known positives at entry 2015 4,750
PMTCT_STAT By: Number of new positives identified 2015 175
PMTCT_STAT Number of new ANC and L&D clients 2015 9,500
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 9,500
PMTCT_STAT Sum of Positives Status disaggregates 2015 4,925
PMTCT_STAT_NGI By: Known positives at entry 2015 4,750
PMTCT_STAT_NGI By: Number of new positives identified 2015 175
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 9,500
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 9,500
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 4,925
PP_PREV Age/sex: 10-14 Female 2015 663
PP_PREV Age/sex: 10-14 Male 2015 663
PP_PREV Age/sex: 15-19 Female 2015 663
PP_PREV Age/sex: 15-19 Male 2015 663
PP_PREV Age/sex: 20-24 Female 2015 663
PP_PREV Age/sex: 20-24 Male 2015 663
PP_PREV Age/sex: 25-49 Female 2015 663
PP_PREV Age/sex: 25-49 Male 2015 663
PP_PREV Age/sex: 50+ Female 2015 96
PP_PREV Age/sex: 50+ Male 2015 100
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2015 5,500
PP_PREV Sum of Age/Sex disaggregates 2015 5,500
PP_PREV Total number of people in the target population 2015 5,500
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 1
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 1
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 1
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 1
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 1
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 1
SITE_SUPP Number of unique sites supported by PEPFAR 2015 1
TB_SCREEN Age: 15-19 2015 350
TB_SCREEN Age: 20-24 2015 392
TB_SCREEN Age: 25-49 2015 1,949
TB_SCREEN Age: 50+ 2015 809
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 3,500
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,500
TB_SCREEN Sex: Female 2015 2,046
TB_SCREEN Sex: Male 2015 1,454
TB_SCREEN Sum of Age disaggregates 2015 350
TB_SCREEN Sum of Aggregated Age disaggregates 2015 3,500
TB_SCREEN Sum of Sex disaggregates 2015 3,500
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 3,500
TX_CURR Age/Sex: <1 Female 2015 60
TX_CURR Age/Sex: <1 Male 2015 60
TX_CURR Age/Sex: 1-4 Female 2015 448
TX_CURR Age/Sex: 1-4 Male 2015 448
TX_CURR Age/Sex: 15+ Female 2015 208
TX_CURR Age/Sex: 15+ Male 2015 208
TX_CURR Age/Sex: 5-14 Female 2015 1,034
TX_CURR Age/Sex: 5-14 Male 2015 1,034
TX_CURR Aggregated Age/Sex: <1 Female 2015 60
TX_CURR Aggregated Age/Sex: <1 Male 2015 60
TX_CURR Aggregated Age/Sex: <15 Female 2015 1,542
TX_CURR Aggregated Age/Sex: <15 Male 2015 1,542
TX_CURR Aggregated Age/Sex: 15+ Female 2015 208
TX_CURR Aggregated Age/Sex: 15+ Male 2015 208
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 3,500
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 1
TX_CURR Sum of age/sex disaggregates 2015 3,084
TX_CURR Sum of Aggregated Age/Sex <15 2015 3,084
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 416
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 3,500
TX_CURR_NGI Age/Sex: <1 Female 2015 60
TX_CURR_NGI Age/Sex: <1 Male 2015 60
TX_CURR_NGI Age/Sex: 1-4 Female 2015 448
TX_CURR_NGI Age/Sex: 1-4 Male 2015 448
TX_CURR_NGI Age/Sex: 15+ Female 2015 208
TX_CURR_NGI Age/Sex: 15+ Male 2015 208
TX_CURR_NGI Age/Sex: 5-14 Female 2015 1,034
TX_CURR_NGI Age/Sex: 5-14 Male 2015 1,034
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 60
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 60
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 1,542
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 1,542
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 208
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 208
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 3,500
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 3,500
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 3,084
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 416
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 3,500
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 1
TX_DIST Total number of PEPFAR supported District Health Offices 2015 1
TX_NEW Aggregated Grouping by Age: <1 Male 2015 17
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 19
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 113
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 121
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 728
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 728
TX_NEW By Age/Sex: <1 Female 2015 19
TX_NEW By Age/Sex: <1 Male 2015 17
TX_NEW By Age/Sex: 1-4 Female 2015 27
TX_NEW By Age/Sex: 1-4 Male 2015 38
TX_NEW By Age/Sex: 10-14 Female 2015 29
TX_NEW By Age/Sex: 10-14 Male 2015 37
TX_NEW By Age/Sex: 15-19 Female 2015 8
TX_NEW By Age/Sex: 15-19 Male 2015 8
TX_NEW By Age/Sex: 20-24 Female 2015 30
TX_NEW By Age/Sex: 20-24 Male 2015 30
TX_NEW By Age/Sex: 25-49 Female 2015 650
TX_NEW By Age/Sex: 25-49 Male 2015 650
TX_NEW By Age/Sex: 5-9 Female 2015 38
TX_NEW By Age/Sex: 5-9 Male 2015 29
TX_NEW By Age/Sex: 50+ Female 2015 40
TX_NEW By Age/Sex: 50+ Male 2015 40
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 1,690
TX_NEW Sum of Age/Sex disaggregates 2015 1,690
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 1,690
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,200
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 1,500
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 275
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 275
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,200
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 2
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 2
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 2
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 2
TX_SITE Total number of PEPFAR-supported ART sites 2015 2
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 2
Key Issues Identified in Mechanism
enumerations.Malaria (PMI)
Child Survival Activities
Safe Motherhood
Tuberculosis
Family Planning